Azeliragon (dihydrochloride)

Azeliragon dihydrochloride (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD) [1]. Azeliragon dihydrochloride also can cross the blood-brain barrier (BBB) [2].

Product Specifications

CAS Number

[1284150-65-7]

Product Name Alternative

TTP488 (dihydrochloride) ; PF-04494700 (dihydrochloride)

UNSPSC

12352005

Target

Amyloid-β

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/azeliragon-dihydrochloride.html

Smiles

CCN(CCCOC1=CC=C(C=C1)C2=CN(C(CCCC)=N2)C3=CC=C(C=C3)OC4=CC=C(C=C4)Cl)CC.Cl.Cl

Molecular Formula

C32H40Cl3N3O2

Molecular Weight

605.04

References & Citations

[1]Bongarzone S, et al. Targeting the Receptor for Advanced Glycation Endproducts (RAGE) : A Medicinal Chemistry Perspective. J Med Chem. 2017 Sep 14;60 (17) :7213-7232.|[2]Burstein AH, et al. Assessment of Azeliragon QTc Liability Through Integrated, Model-Based Concentration QTc Analysis. Clin Pharmacol Drug Dev. 2019 May;8 (4) :426-435.|[3]Chen Y, et al. RAGE ligation affects T cell activation and controls T cell differentiation. J Immunol. 2008 Sep 15;181 (6) :4272-8.